JP7229565B2 - メラノーマを治療するための方法 - Google Patents
メラノーマを治療するための方法 Download PDFInfo
- Publication number
- JP7229565B2 JP7229565B2 JP2020550082A JP2020550082A JP7229565B2 JP 7229565 B2 JP7229565 B2 JP 7229565B2 JP 2020550082 A JP2020550082 A JP 2020550082A JP 2020550082 A JP2020550082 A JP 2020550082A JP 7229565 B2 JP7229565 B2 JP 7229565B2
- Authority
- JP
- Japan
- Prior art keywords
- melanoma
- tumor
- cells
- dapanthril
- olt1177
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862645999P | 2018-03-21 | 2018-03-21 | |
| US62/645,999 | 2018-03-21 | ||
| PCT/US2019/022770 WO2019182981A1 (en) | 2018-03-21 | 2019-03-18 | Methods for treating melanoma |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021518374A JP2021518374A (ja) | 2021-08-02 |
| JP2021518374A5 JP2021518374A5 (cg-RX-API-DMAC7.html) | 2022-03-15 |
| JP7229565B2 true JP7229565B2 (ja) | 2023-02-28 |
Family
ID=67987925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020550082A Active JP7229565B2 (ja) | 2018-03-21 | 2019-03-18 | メラノーマを治療するための方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11857529B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3768384B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7229565B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN111867678B (cg-RX-API-DMAC7.html) |
| CA (1) | CA3094307A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2020009552A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019182981A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12121565B2 (en) * | 2019-09-13 | 2024-10-22 | Duke University | Methods of treatment of specific cancers with NLRP3 inhibitors and anti-PD1/PD-L1 antibodies |
| EP4045009A4 (en) * | 2019-10-14 | 2023-11-01 | Olatec Therapeutics LLC | METHOD FOR TREATING BREAST CANCER |
| EP4387729A4 (en) * | 2021-08-19 | 2025-07-09 | Olatec Therapeutics Inc | METHODS OF TREATMENT OF PARKINSON'S DISEASE |
| WO2026035767A1 (en) * | 2024-08-06 | 2026-02-12 | Olatec Therapeutics, Inc. | Methods for treating melanoma metastasis to liver and lungs |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016176504A1 (en) | 2015-04-28 | 2016-11-03 | Bristol-Myers Squibb Company | Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody |
| JP2020503358A (ja) | 2017-01-06 | 2020-01-30 | オラテック セラピューティクス リミティド ライアビリティ カンパニー | 心血管疾患を治療する方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2013006708A (es) * | 2010-12-15 | 2013-09-13 | Olatec Ind Llc | Composicion de 3-metanosulfonilpropionitrilo para el tratamiento de la inflamacion y el dolor. |
| CA2875053C (en) * | 2012-06-05 | 2020-07-14 | Olatec Industries Llc | Pharmaceutical composition for treating inflammation and pain |
| JP6185575B2 (ja) * | 2012-06-05 | 2017-08-23 | オラテック セラピューティクス リミティド ライアビリティ カンパニー | 皮膚炎症性疾患の治療方法 |
| JP6929792B2 (ja) * | 2015-02-16 | 2021-09-01 | ザ ユニバーシティ オブ クィーンズランド | スルホニル尿素及び関連化合物並びにその使用 |
| EP3445761A1 (en) * | 2016-04-19 | 2019-02-27 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
| NL2017267B1 (en) * | 2016-07-29 | 2018-02-01 | Aduro Biotech Holdings Europe B V | Anti-pd-1 antibodies |
| EP3589370A4 (en) * | 2017-01-06 | 2020-11-18 | Olatec Therapeutics LLC | MULTIPLE SCLEROSIS TREATMENT METHOD |
| US20210254056A1 (en) | 2017-05-05 | 2021-08-19 | Camp4 Therapeutics Corporation | Identification and targeted modulation of gene signaling networks |
| WO2019152627A1 (en) * | 2018-01-31 | 2019-08-08 | Olatec Therapeutics Llc | Method for preventing or treating alzheimer's disease |
-
2019
- 2019-03-18 JP JP2020550082A patent/JP7229565B2/ja active Active
- 2019-03-18 CN CN201980020523.3A patent/CN111867678B/zh active Active
- 2019-03-18 WO PCT/US2019/022770 patent/WO2019182981A1/en not_active Ceased
- 2019-03-18 CA CA3094307A patent/CA3094307A1/en active Pending
- 2019-03-18 EP EP19771591.5A patent/EP3768384B1/en active Active
- 2019-03-18 MX MX2020009552A patent/MX2020009552A/es unknown
-
2020
- 2020-09-15 US US17/021,733 patent/US11857529B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016176504A1 (en) | 2015-04-28 | 2016-11-03 | Bristol-Myers Squibb Company | Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody |
| JP2020503358A (ja) | 2017-01-06 | 2020-01-30 | オラテック セラピューティクス リミティド ライアビリティ カンパニー | 心血管疾患を治療する方法 |
Non-Patent Citations (2)
| Title |
|---|
| Proceeding of the National Academy of Sciences of the United States of America,2018年01月29日,Vol.115, No.7,p.E1530-E1539 |
| Toxicology and Applied Pharmacology,2013年,Vol.279, No.1,p.70-76 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021518374A (ja) | 2021-08-02 |
| WO2019182981A1 (en) | 2019-09-26 |
| CN111867678A (zh) | 2020-10-30 |
| EP3768384A4 (en) | 2021-11-17 |
| EP3768384B1 (en) | 2025-06-25 |
| CA3094307A1 (en) | 2019-09-26 |
| US20200405681A1 (en) | 2020-12-31 |
| EP3768384A1 (en) | 2021-01-27 |
| MX2020009552A (es) | 2020-10-05 |
| US11857529B2 (en) | 2024-01-02 |
| CN111867678B (zh) | 2023-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11857529B2 (en) | Methods for treating melanoma | |
| JP7671327B2 (ja) | 消化管間質腫瘍の治療のための併用療法 | |
| US20130129675A1 (en) | Interferon therapies in combination with blockade of stat3 activation | |
| BR112019024135A2 (pt) | Terapias de combinação para o tratamento de câncer | |
| KR20180094989A (ko) | 노화 관련 인지장애 및 신경염증의 예방 및/또는 치료 방법 | |
| US12582628B2 (en) | Methods for treating breast cancer | |
| Pavia et al. | Generalized pustular psoriasis flare in a patient affected by plaque psoriasis after BNT162b2 mRNA COVID‐19 vaccine, successfully treated with risankizumab | |
| US11517575B2 (en) | Use of minaprine to reduce tumor growth | |
| CN108139403A (zh) | 用于组合疗法的患者的选择 | |
| WO2018083704A1 (en) | Use of hexokinase 2/mitochondria-detaching compounds for activating immune responses | |
| JP2011506436A (ja) | 細胞傷害性tリンパ球抗原4(ctla4)に対する抗体と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法 | |
| KR20090020646A (ko) | 4기 악성 흑색종의 치료를 위한 약제의 제조를 위한 티모신알파 1의 용도 | |
| KR101978108B1 (ko) | 암 세포의 대사 특이성에 기초하는 신규 항 악성 종양제 | |
| Donskov et al. | Outpatient treatment with subcutaneous histamine dihydrochloride in combination with interleukin-2 and interferon-α in patients with metastatic renal cell carcinoma: results of an open single-armed multicentre phase II study | |
| EP3664786B1 (en) | Method for treating schnitzler's syndrome | |
| Keshavarz et al. | Multi-tyrosine kinase inhibitors: exploring immunomodulatory effects on various immune cell types in cancer | |
| JP7648155B2 (ja) | プロカスパーゼ‐3の活性化及びがんの治療のための免疫療法 | |
| US20240417812A1 (en) | Methods for treating solid cancer patients with clonal hematopoiesis of indeterminate potential | |
| Madleen et al. | Metabolic and immunological phenotype of rare lipomatoses: Dercum’s disease and Roch-Leri mesosomatic lipomatosis | |
| Sakr et al. | Modulation of proinflammatory cytokines and leukocyte mobilization by melatonin in response to sterile tissue injury in Wistar albino rats | |
| KR20200124661A (ko) | 종양 성장을 감소시키기 위한 미나프린의 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220307 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220307 |
|
| TRDD | Decision of grant or rejection written | ||
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20221223 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230110 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230208 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7229565 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |